European Commission Approves KEYTRUDA® as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection Life Science Investing
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors Pharmaceutical Investing
Treatment With Hepcludex® Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks Pharmaceutical Investing
BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference Pharmaceutical Investing
CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE as an Option for Pneumococcal Vaccination in Infants and Children Life Science Investing
MAVIRET® Approved by Health Canada for Paediatric Patients with Chronic Hepatitis C Pharmaceutical Investing
Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing Life Science Investing
U.S. FDA Approves Merck's VAXNEUVANCE for the Prevention of Invasive Pneumococcal Disease in Infants and Children Life Science Investing
Results From Phase 3 PROpel Trial of LYNPARZA® Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence Life Science Investing
